Degache F.,University of Lausanne |
Guex K.,University of Applied Sciences and Arts Western Switzerland |
Fourchet F.,Aspire Health |
Morin J.B.,Jean Monnet University |
And 3 more authors.
Journal of Sports Sciences | Year: 2013
The aim of this study was to investigate changes in running mechanics and spring-mass behaviour with fatigue induced by 5-hour hilly running (5HHR). Running mechanics were measured pre- and post-5HHR at 10, 12 and 14 km · h-1 on an instrumented treadmill in eight ultramarathon runners, and sampled at 1000 Hz for 10 consecutive steps. Contact (tc) and aerial (ta) times were determined from ground reaction force (GRF) signals and used to compute step frequency (f). Maximal GRF, loading rate, downward displacement of the centre of mass (Δz), and leg length change (ΔL) during the support phase were determined and used to compute both vertical (Kvert) and leg (Kleg) stiffness. A significant decrease in tc was observed at 12 and 14 km · h-1 resulting in an increase of f at all speeds. Duty factor and Fmax significantly decreased at 10 km · h-1. A significant increase in Kvert and Kleg was observed at all running speeds with significant decreases in Δz and ΔL. Despite the shorter duration, the changes in running mechanics appeared to be in the same direction (increased f and Kvert, decrease in Δz and Fmax) but of lower amplitude compared with those obtained after an ultra-trail or an ultramarathon. © 2013 Copyright Taylor and Francis Group, LLC.
Sigalet E.,University of Calgary |
Donnon T.,University of Calgary |
Cheng A.,University of Calgary |
Cooke S.,University of Calgary |
And 3 more authors.
Academic Medicine | Year: 2013
PURPOSE: Interprofessional simulation-based team training is strongly endorsed as a potential solution for improving teamwork in health care delivery. Unfortunately, there are few teamwork evaluation instruments. The present study developed and tested the psychometric characteristics of the newly developed KidSIM Team Performance Scale checklist. METHOD: A quasi-experimental research design engaging a convenience sample of 196 undergraduate medical, nursing, and respiratory therapy students was completed in the 2010-2011 academic year. Multidisciplinary student teams participated in a simulation-based curriculum that included the completion of two acute illness management scenarios, resulting in 282 independent reviews by evaluators from medicine, nursing, and respiratory therapy. The authors investigated the underlying factors of the performance checklist and examined the performance scores of an experimental and a control team-training-curriculum group. RESULTS: Participation in the supplemental team training curriculum was related to higher team performance scores (P < .001). All teams at Time 2 achieved higher scores than at Time 1 (P < .05). The reliability coefficient for the total performance scale was α = 0.90. Factor analysis supported a three-factor solution (accounting for 67.9% of the variance) with an emphasis on roles and responsibilities (five items) and communication (six items) subscale factors. CONCLUSIONS: When simulation is used in acute illness management training, the KidSIM Team Performance Scale provides reliable, valid score interpretation of undergraduates' team process based on communication effectiveness and identification of roles and responsibilities. Implementation of a supplementary team training curriculum significantly enhances students' performance in multidisciplinary simulation-based scenarios at the undergraduate level.
News Article | June 2, 2015
Top News in the A.M. All United Airlines flights in the U.S. were grounded this morning for nearly an hour over “dispatching information.” Wired has more here. Bessemer’s Byron Deeter on the Future of Cloud Companies Like many venture firms, Bessemer Venture Partners provides all manner of perks for its CEOs, including a day of race-car driving and wine tasting. Today, in San Francisco, the firm will be providing its CEOs with a different kind of perk. Together with Salesforce Ventures, Bessemer is hosting a day-long “cloud” summit that brings together CEOs backed by the two outfits to share best practices, let them learn from each other, and to dazzle them with speakers like quarterback-turned-investor Steve Young and the futurist Ray Kurzweil. Yesterday, we caught up with longtime Bessemer partner Byron Deeter, who organized the event, and who has led deals in numerous high-flying cloud companies — including the online storage service Box, the app-building software service Twilio, and the digital signatures specialist DocuSign – to learn more. What are you hoping these CEOs will learn today? Part of the event is just understanding where we are. Analysts are now predicting that midway through next year, the majority of application revenue in [customer relationship management] will be cloud-based, which is a tipping point we’ve long been predicting. More broadly, we’ve beentracking public cloud companies for a while now, and based on our data analysis, we’ve come to believe this group will have a combined market cap of half a trillion dollars by 2020, up from $180 billion today — which is itself up from $40 billion three years ago. As an investor looking to make two bets per year, roughly, where are you spending your time? What sub themes do you think are most interesting right now? I’ve personally been most active in industry cloud and enterprise mobile, which is finally coming of age. Industry cloud is really this notion of the “verticalization” of software and the opportunity for a large vendor like Veeva [which makes cloud-based software for the life sciences industry] or Athena Health [which provides its customers with electronic health records, revenue cycle management, and more] or Shopify [which juggles all kinds of store management issues for its retailer customers] to create dedicated [cloud-based] software for a dedicated industry group. And these models can have massive success. And enterprise mobile? We have to admit that long-suffering Good Technology [among the first startups to provide email access via mobile devices] still springs to mind whenever we hear those words. We founded Visto [which acquired Good in 2009 and took its name] at Bessemer [in 1996]. Early investors lost money, but out of the wreckage has emerged a valuable business. It represents some of the challenges of entering a market before it’s ready. Being early is the same as being wrong if you’re just too aggressive and run out of money before the market comes to you. Now, with the penetration of smart phones, internet usage is tipping to mobile and empowering a workforce of people who have smart phones but don’t sit in front of a PC all day. And this is just the early days of that opportunity. Privately held cloud companies are trading at multiples well above their public market counterparts. It’s about double the public company multiples for the hottest late-stage private companies, which is unusual in that private companies used to trade at a discount to public comps because they were illiquid. Does this now years-long trend concern you? Well, it’s very hard to lead new investments in late-stage cloud companies because many are priced to perfection. You have all these groups – late stage investors, private equity investors, crossover public investors – that want exposure to hypergrowth and that are being aggressive about it, and they’re combining to drive up valuations. In many cases, they’ve been rewarded for their actions, too, with very positive, profitable returns. But companies are also staying private longer as a result. I think you need to disconnect the two. Investors can invest at any stage and, within reason, still have very positive results. That’s separate from when the company chooses to go public. Does it make sense to wait [on an IPO]? I do think companies are overthinking it and waiting too long. When they have strong businesses with proven business models, waiting to grow from $2 billion to $10 billion in market cap makes less sense. Many are staying private for the right reasons, though, [such as] to work through business model and strategic issues. Bessemer is the largest shareholder in Pinterest. Does it make sense for Pinterest to go public any time soon? It doesn’t. Pinterest is still refining its business model, and that’s best done as a private company, where you can take a lot of risk and not have to report on every action in a public setting.
News Article | June 1, 2015
NASHVILLE, Tenn. & GREENWICH, Conn.--(BUSINESS WIRE)--Aspire Health (“Aspire”), the nation’s largest provider of home and outpatient-based palliative care announced $15 million in Series C funding. The investment was led by Oak HC/FT, a premier venture growth-equity fund focused on healthcare information and financial technology. “Demand for specialized medical care by patients facing a serious illness has increased rapidly in the U.S.,” said Annie Lamont, managing partner at Oak HC/FT. “Aspire Health is serving this important and growing segment of the healthcare market by delivering cost-effective, personalized palliative care services that patients and their families seek. We are excited to invest in their growth and support the continued expansion of palliative care in the U.S.” Brad Smith, chief executive officer of Aspire Health, added, “We are thrilled to partner with Oak HC/FT, which has one of the best track-records in the country at backing leading, high-growth healthcare companies. Their support will enable Aspire to invest in additional data analytics, IT infrastructure and growth into new markets.” The quality and cost of care for patients approaching the end of life has drawn increasing attention, with research showing that more than a quarter of Medicare expenditures go to care for patients in the last year of life. Aspire currently operates 11 palliative care practices across 16 cities in seven states and their existing healthcare partners include Cigna-HealthSpring, Blue Cross Blue Shield of Tennessee, Highmark, Humana and Aetna, among others. Since its founding in July 2013, Aspire has received an average rating of 4.9 out of 5 for patient satisfaction on internal customer surveys. Ms. Lamont, who ranked first among the leading healthcare investors on the 2015 Midas List, will join Aspire Health’s board of directors, which is chaired by former U.S. Senate Majority Leader Bill Frist, one of the ten most influential healthcare figures in the U.S., according to Modern Healthcare Magazine. Aspire Health is a home and outpatient-based palliative care provider that operates a group of specialized physician practices that care for patients facing a serious illness. Aspire was co-founded by Senator Bill Frist, a physician, and is based in Nashville, Tennessee. Additional information on Aspire Health can be found at www.aspirehealthcare.com. Oak HC/FT (http://oakhcft.com/) is the premier venture growth-equity fund investing in Healthcare Information & Services ("HC") and Financial Services Technology ("FT"). We are focused on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, business plan execution and access to our extensive network of industry leaders.
Home > Press > Silver nanoparticles' protein 'corona' affects their toxicity: Scientists distinguished how protein 'corona' of silver nanoparticles affects their cellular toxicity Abstract: A senior fellow at the Faculty of Chemistry, MSU, Vladimir Bochenkov together with his colleagues from Denmark succeeded in deciphering the mechanism of interaction of silver nanoparticles with the cells of the immune system. The study is published in the journal Nature Communications. 'Currently, a large number of products are containing silver nanoparticles: antibacterial drugs, toothpaste, polishes, paints, filters, packaging, medical and textile items. The functioning of these products lies in the capacity of silver to dissolve under oxidation and form ions Ag+ with germicidal properties. At the same time there are research data in vitro, showing the silver nanoparticles toxicity for various organs, including the liver, brain and lungs. In this regard, it is essential to study the processes occurring with silver nanoparticles in biological environments, and the factors affecting their toxicity,' says Vladimir Bochenkov. The study is devoted to the protein corona -- a layer of adsorbed protein molecules, which is formed on the surface of the silver nanoparticles during their contact with the biological environment, for example in blood. Protein crown masks nanoparticles and largely determines their fate: the speed of the elimination from the body, the ability to penetrate to a particular cell type, the distribution between the organs, etc. According to the latest research, the protein corona consists of two layers: a rigid hard corona -- protein molecules tightly bound with silver nanoparticles, and soft corona, consisting of weakly bound protein molecules in a dynamic equilibrium with the solution. Hitherto soft corona has been studied very little because of the experimental difficulties: the weakly bound nanoparticles separated from the protein solution easily desorbed (leave a particle remaining in the solution), leaving only the rigid corona on the nanoparticle surface. The size of the studied silver nanoparticles was of 50-88 nm, and the diameter of the proteins that made up the crown -- 3-7 nm. Scientists managed to study the silver nanoparticles with the protein corona in situ, not removing them from the biological environment. Due to the localized surface plasmon resonance used for probing the environment near the surface of the silver nanoparticles, the functions of the soft corona have been primarily investigated. 'In the work we showed that the corona may affect the ability of the nanoparticles to dissolve to silver cations Ag+, which determine the toxic effect. In the absence of a soft corona (quickly sharing the medium protein layer with the environment) silver cations are associated with the sulfur-containing amino acids in serum medium, particularly cysteine and methionine, and precipitate as nanocrystals Ag2S in the hard corona,' says Vladimir Bochenkov. Ag2S (silver sulfide) famously easily forms on the silver surface even on the air in the presence of the hydrogen sulfide traces. Sulfur is also part of many biomolecules contained in the body, provoking the silver to react and be converted into sulfide. Forming of the nano-crystals Ag2S due to low solubility reduces the bioavailability of the Ag+ ions, reducing the toxicity of silver nanoparticles to null. With a sufficient amount of amino acid sulfur sources available for reaction, all the potentially toxic silver is converted into the nontoxic insoluble sulfide. Scientists have shown that what happens in the absence of a soft corona. In the presence of a soft corona, the Ag2S silver sulfide nanocrystals are formed in smaller quantities or not formed at all. Scientists attribute this to the fact that the weakly bound protein molecules transfer the Ag+ ions from nanoparticles into the solution, thereby leaving the sulfide not crystallized. Thus, the soft corona proteins are 'vehicles' for the silver ions. This effect, scientists believe, be taken into account when analyzing the stability of silver nanoparticles in a protein environment, and in interpreting the results of the toxicity studies. Studies of the cells viability of the immune system (J774 murine line macrophages) confirmed the reduction in cell toxicity of silver nanoparticles at the sulfidation (in the absence of a soft corona). Vladimir Bochenkov's challenge was to simulate the plasmon resonance spectra of the studied systems and to create the theoretical model that allowed quantitative determination of silver sulfide content in situ around nanoparticles, following the change in the absorption bands in the experimental spectra. Since the frequency of the plasmon resonance is sensitive to a change in dielectric constant near the nanoparticle surface, changes in the absorption spectra contain information about the amount of silver sulfide formed. Knowledge of the mechanisms of formation and dynamics of the behavior of the protein corona, information about its composition and structure are extremely important for understanding the toxicity and hazards of nanoparticles for the human body. In prospect the protein corona formation can be used to deliver drugs in the body, including the treatment of cancer. For this purpose it will be enough to pick such a content of the protein corona, which enables silver nanoparticles penetrate only in the cancer cell and kill it. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.